Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Pfizer NicOx Inc. |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00441883 |
This study will evaluate the safety and efficacy of PF 03187207.
Condition | Intervention | Phase |
---|---|---|
Primary Open Angle Glaucoma Ocular Hypertension Pigmentary Glaucoma Pseudoexfoliative Glaucoma |
Drug: PF-03187207 Drug: latanoprost |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Efficacy Study |
Official Title: | A Phase 2, 28 Day Parallel-Group, Double-Masked, Dose-Finding Study Comparing the Safety and Efficacy of PF-03187207 to Latanoprost |
Estimated Enrollment: | 216 |
Study Start Date: | March 2007 |
Study Completion Date: | March 2008 |
Primary Completion Date: | February 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Active: Active Comparator |
Drug: latanoprost
1 drop, once a day, per dosed eye for duration of study.
|
Experimental: Experimental |
Drug: PF-03187207
1 drop, once a day, per dosed eye for duration of study.
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
-Closed or barely open anterior chamber angle or a history of acute angle closure in either eye
United States, California | |
Pfizer Investigational Site | |
Newport Beach, California, United States, 92663 | |
Pfizer Investigational Site | |
Artesia, California, United States, 90701 | |
Pfizer Investigational Site | |
Petaluma, California, United States, 94954 | |
Pfizer Investigational Site | |
Poway, California, United States, 92064 | |
United States, Connecticut | |
Pfizer Investigational Site | |
Danbury, Connecticut, United States, 06810-4004 | |
United States, Florida | |
Pfizer Investigational Site | |
Ormond Beach, Florida, United States, 32174 | |
Pfizer Investigational Site | |
Jacksonville, Florida, United States, 32204 | |
United States, Georgia | |
Pfizer Investigational Site | |
Atlanta, Georgia, United States, 30339 | |
Pfizer Investigational Site | |
Atlanta, Georgia, United States, 30342 | |
United States, Indiana | |
Pfizer Investigational Site | |
Evansville, Indiana, United States, 47710 | |
United States, Kentucky | |
Pfizer Investigational Site | |
Louisville, Kentucky, United States, 40217 | |
United States, New York | |
Pfizer Investigational Site | |
Rochester, New York, United States, 14618 | |
United States, North Carolina | |
Pfizer Investigational Site | |
High Point, North Carolina, United States, 27262 | |
Pfizer Investigational Site | |
Charlotte, North Carolina, United States, 28210 | |
United States, Oklahoma | |
Pfizer Investigational Site | |
Tulsa, Oklahoma, United States, 74104 | |
United States, Pennsylvania | |
Pfizer Investigational Site | |
Cranberry Township, Pennsylvania, United States, 16066 | |
Pfizer Investigational Site | |
Pittsburgh, Pennsylvania, United States, 15238 | |
United States, Tennessee | |
Pfizer Investigational Site | |
Memphis, Tennessee, United States, 38119 | |
United States, Texas | |
Pfizer Investigational Site | |
Austin, Texas, United States, 78705 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer Inc ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A9441001 |
Study First Received: | February 27, 2007 |
Last Updated: | April 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00441883 |
Health Authority: | United States: Food and Drug Administration |
Signs and Symptoms Glaucoma Eye Diseases Glaucoma, Open-Angle |
Vascular Diseases Latanoprost Hypertension Ocular Hypertension |
Therapeutic Uses Cardiovascular Diseases Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |